Abstracts

SOFOSBUVIR/VELPATASVIR PHARMACOKINETICS IN PREGNANT WOMEN WITH HEPATITIS C VIRUS

Background: Treatment of hepatitis C virus (HCV) with direct acting antivirals during pregnancy could cure maternal HCV during antenatal care engagement and prevent perinatal HCV transmission. A study of ledipasvir/sofosbuvir in pregnancy (NCT02683005) showed good efficacy and favorable pharmacokinetics (PK), but a pan-genotypic regimen was needed. Our objectives were to compare the PK parameters of…

HEPATITIS C TREATMENT OUTCOMES AMONG PEOPLE WHO INJECT DRUGS IN KENYA

Background: Hepatitis C virus (HCV) is a growing public health concern with approximately 1.5 million infections occurring annually globally. Direct-acting-antivirals (DAAs) are highly efficacious in treating HCV and strategies tailored for disproportionally affected groups such as people who inject drugs (PWID) are needed for early identification and treatment of infected individuals. Methods: We assessed factors…

GENERATING BROADLY NEUTRALIZING ANTIBODY-SECRETING CAR-T CELLS AGAINST HIV INFECTION

Background: Treatment with HIV-specific CAR-T cells and broadly neutralizing antibodies (bNAbs) are both important approaches to potentially provide the sustained anti-HIV activity required to achieve ART-free HIV remission. We hypothesized that the anti-HIV activity of CAR-T cells could be further increased by enabling them to secrete bNAbs. As a proof-of-concept, we engineered a lentiviral vector…